209 related articles for article (PubMed ID: 32851809)
1. Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral Venglustat in Healthy Volunteers.
Peterschmitt MJ; Crawford NPS; Gaemers SJM; Ji AJ; Sharma J; Pham TT
Clin Pharmacol Drug Dev; 2021 Jan; 10(1):86-98. PubMed ID: 32851809
[TBL] [Abstract][Full Text] [Related]
2. Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson's Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD Trial.
Peterschmitt MJ; Saiki H; Hatano T; Gasser T; Isaacson SH; Gaemers SJM; Minini P; Saubadu S; Sharma J; Walbillic S; Alcalay RN; Cutter G; Hattori N; Höglinger GU; Marek K; Schapira AHV; Scherzer CR; Simuni T; Giladi N; Sardi SP; Fischer TZ;
J Parkinsons Dis; 2022; 12(2):557-570. PubMed ID: 34897099
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, Safety, and Tolerability of Single-Dose Orally Administered Venglustat in Healthy Chinese Volunteers.
Li Y; Li Y; Li L; Xue W; Xin K; Wang T; Shi A
Clin Drug Investig; 2023 Jun; 43(6):413-420. PubMed ID: 37269489
[TBL] [Abstract][Full Text] [Related]
4. Phase 1 Healthy Volunteer Study of AL01211, an Oral, Non-brain Penetrant Glucosylceramide Synthase Inhibitor, to Treat Fabry Disease and Type 1 Gaucher Disease.
Babcock M; Zheng J; Gail Shurr J; Li L; Wang B; Huertas P; Ryan PJ; Shen Y; Garovoy M
Clin Pharmacol Drug Dev; 2024 Jun; 13(6):696-709. PubMed ID: 38363061
[TBL] [Abstract][Full Text] [Related]
5. Venglustat combined with imiglucerase for neurological disease in adults with Gaucher disease type 3: the LEAP trial.
Schiffmann R; Cox TM; Dedieu JF; Gaemers SJM; Hennermann JB; Ida H; Mengel E; Minini P; Mistry P; Musholt PB; Scott D; Sharma J; Peterschmitt MJ
Brain; 2023 Feb; 146(2):461-474. PubMed ID: 36256599
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral AL01211 in Healthy Chinese Volunteers.
Dong L; Xiang J; Babcock M; Cheng Y; Wang Y; Shen Y; Li L; Tan L; Garovoy M; Hu W; Zheng J
Clin Drug Investig; 2024 Jun; 44(6):387-398. PubMed ID: 38698285
[TBL] [Abstract][Full Text] [Related]
7. Venglustat, an orally administered glucosylceramide synthase inhibitor: Assessment over 3 years in adult males with classic Fabry disease in an open-label phase 2 study and its extension study.
Deegan PB; Goker-Alpan O; Geberhiwot T; Hopkin RJ; Lukina E; Tylki-Szymanska A; Zaher A; Sensinger C; Gaemers SJM; Modur V; Thurberg BL; Sharma J; Najafian B; Mauer M; DasMahapatra P; Wilcox WR; Germain DP
Mol Genet Metab; 2023 Feb; 138(2):106963. PubMed ID: 36481125
[TBL] [Abstract][Full Text] [Related]
8. Safety, tolerability, and pharmacokinetics of eliglustat tartrate (Genz-112638) after single doses, multiple doses, and food in healthy volunteers.
Peterschmitt MJ; Burke A; Blankstein L; Smith SE; Puga AC; Kramer WG; Harris JA; Mathews D; Bonate PL
J Clin Pharmacol; 2011 May; 51(5):695-705. PubMed ID: 20864621
[TBL] [Abstract][Full Text] [Related]
9. Preclinical pharmacology of glucosylceramide synthase inhibitor venglustat in a GBA-related synucleinopathy model.
Viel C; Clarke J; Kayatekin C; Richards AM; Chiang MSR; Park H; Wang B; Shihabuddin LS; Sardi SP
Sci Rep; 2021 Oct; 11(1):20945. PubMed ID: 34686711
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Enzyme and Substrate Reduction Therapy with a Novel Antagonist of Glucosylceramide Synthase for Fabry Disease.
Ashe KM; Budman E; Bangari DS; Siegel CS; Nietupski JB; Wang B; Desnick RJ; Scheule RK; Leonard JP; Cheng SH; Marshall J
Mol Med; 2015 Apr; 21(1):389-99. PubMed ID: 25938659
[TBL] [Abstract][Full Text] [Related]
11. Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2/3 Randomized Clinical Trial.
Gansevoort RT; Hariri A; Minini P; Ahn C; Chapman AB; Horie S; Knebelmann B; Mrug M; Ong ACM; Pei YPC; Torres VE; Modur V; Antonshchuk I; Perrone RD
Am J Kidney Dis; 2023 May; 81(5):517-527.e1. PubMed ID: 36535535
[TBL] [Abstract][Full Text] [Related]
12. First-in-human single-dose study of nizubaglustat, a dual inhibitor of ceramide glucosyltransferase and non-lysosomal glucosylceramidase: Safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending and multiple doses in healthy adults.
Paquet Luzy C; Doppler E; Polasek TM; Giorgino R
Mol Genet Metab; 2024 Jan; 141(1):108113. PubMed ID: 38113551
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamics, pharmacokinetics, safety, and tolerability of encenicline, a selective α7 nicotinic receptor partial agonist, in single ascending-dose and bioavailability studies.
Barbier AJ; Hilhorst M; Van Vliet A; Snyder P; Palfreyman MG; Gawryl M; Dgetluck N; Massaro M; Tiessen R; Timmerman W; Hilt DC
Clin Ther; 2015 Feb; 37(2):311-24. PubMed ID: 25438724
[TBL] [Abstract][Full Text] [Related]
14. Substrate Reduction Therapy for Sandhoff Disease through Inhibition of Glucosylceramide Synthase Activity.
Marshall J; Nietupski JB; Park H; Cao J; Bangari DS; Silvescu C; Wilper T; Randall K; Tietz D; Wang B; Ying X; Leonard JP; Cheng SH
Mol Ther; 2019 Aug; 27(8):1495-1506. PubMed ID: 31208914
[TBL] [Abstract][Full Text] [Related]
15. CNS-accessible Inhibitor of Glucosylceramide Synthase for Substrate Reduction Therapy of Neuronopathic Gaucher Disease.
Marshall J; Sun Y; Bangari DS; Budman E; Park H; Nietupski JB; Allaire A; Cromwell MA; Wang B; Grabowski GA; Leonard JP; Cheng SH
Mol Ther; 2016 Jun; 24(6):1019-1029. PubMed ID: 26948439
[TBL] [Abstract][Full Text] [Related]
16. Impact of the organic cation transporter 2 inhibitor cimetidine on the single-dose pharmacokinetics of the glucosylceramide synthase inhibitor lucerastat in healthy subjects.
Boof ML; Halabi A; Ufer M; Dingemanse J
Eur J Clin Pharmacol; 2020 Mar; 76(3):431-437. PubMed ID: 31836927
[TBL] [Abstract][Full Text] [Related]
17. Assessment of Target Engagement in a First-in-Human Trial with Sinbaglustat, an Iminosugar to Treat Lysosomal Storage Disorders.
Gehin M; Melchior M; Welford RWD; Sidharta PN; Dingemanse J
Clin Transl Sci; 2021 Mar; 14(2):558-567. PubMed ID: 33142037
[TBL] [Abstract][Full Text] [Related]
18. Safety, Tolerability and Pharmacokinetics of FAAH Inhibitor V158866: A Double-Blind, Randomised, Placebo-Controlled Phase I Study in Healthy Volunteers.
Pawsey S; Wood M; Browne H; Donaldson K; Christie M; Warrington S
Drugs R D; 2016 Jun; 16(2):181-91. PubMed ID: 26987975
[TBL] [Abstract][Full Text] [Related]
19. Lucerastat, an iminosugar with potential as substrate reduction therapy for glycolipid storage disorders: safety, tolerability, and pharmacokinetics in healthy subjects.
Guérard N; Morand O; Dingemanse J
Orphanet J Rare Dis; 2017 Jan; 12(1):9. PubMed ID: 28088251
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics, safety, and tolerability of GLPG0259, a mitogen-activated protein kinase-activated protein kinase 5 (MAPKAPK5) inhibitor, given as single and multiple doses to healthy male subjects.
Namour F; Vanhoutte FP; Beetens J; Blockhuys S; De Weer M; Wigerinck P
Drugs R D; 2012 Sep; 12(3):141-63. PubMed ID: 22950522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]